Clinical Report: Genetic Variants in GCKR and Circulating FGF21 as Indicators of Metabolic Risk

Overview

Revise to specify the genetic variants studied and their implications for MASLD and MASH.

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant and growing health concern, linked to obesity and metabolic syndrome. The condition can progress to more severe forms, such as MASH, which increases the risk of serious liver complications. Identifying non-invasive biomarkers for early detection and risk stratification is critical for improving patient outcomes.

Data Highlights

No specific numerical data or trial data provided in the source material.

Key Findings

• GCKR rs1260326 variant is associated with enhanced hepatic glucose flux and triglyceride synthesis.
• FGF21 levels are elevated in obesity and fatty liver disease, indicating a compensatory response to metabolic stress.
• Both GCKR and FGF21 genetic variants may contribute to the transition from MASLD to MASH.
• Prior studies have shown that GCKR polymorphisms influence metabolic traits, while FGF21 reflects metabolic stress responses.
• The study emphasizes the need for integrated evaluation of genetic markers in MASLD.

Clinical Implications

Healthcare professionals should consider the role of genetic variants in GCKR and FGF21 when assessing patients for MASLD. These markers may provide valuable insights into individual risk profiles and guide early intervention strategies.

Conclusion

The findings underscore the importance of genetic factors in MASLD and their potential utility as non-invasive biomarkers for disease progression. Further research is warranted to validate these associations in clinical practice.

References

1. GCKR genetic variants and circulating FGF21 identify a metabolic risk signature in metabolic dysfunction-associated steatotic liver disease, BMC Gastroenterology, 2026 -- Title
2. Growth Differentiation Factor 15: Transitioning from Stress Marker to Clinical Application in Chronic Liver Disorders, Journal of Gastroenterology, 2025 -- Title
3. Association of Hepatic IRS1 and ß-catenin Levels with Histological Progression and Development of Diabetes in Patients with NAFLD, Journal of Gastroenterology, 2018 -- Title
4. Utilizing Machine Learning for the Discovery of Biomarkers Aiding in the Early Detection of Metabolic Dysfunction–Associated Steatotic Liver Disease, The Journal of Clinical Endocrinology & Metabolism, 2025 -- Title
5. Clinical Assessment and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease | AASLD, AASLD -- Title
6. npj Digital Medicine — Combining Multi-Omics Approaches with Machine Learning to Unravel Cellular Diversity and Fibrotic Regulatory Pathways in the Transition from MASLD to MASH
7. Current guidance on MASLD care and management, AASLD
8. Combining Multi-Omics Approaches with Machine Learning to Unravel Cellular Diversity and Fibrotic Regulatory Pathways in the Transition from MASLD to MASH, npj Digital Medicine
9. GCKR genetic variants and circulating FGF21 identify a metabolic risk signature in metabolic dysfunction-associated steatotic liver disease | BMC Gastroenterology | Springer Nature Link
10. Positive longer-term results for efruxifermin in MASH | Nature Reviews Gastroenterology & Hepatology